Drug Trial Radar · NCT02504489
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
559
Actual
Start
Dec 2015
Primary completion
Jul 21, 2021
Study completion Oct 30, 2023
Sponsor
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: * To compare overall response rate (ORR) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare progression free survival (PFS) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare incidence of Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 109/L) on Day 8 (+/- 1 day) of Cycle 1 of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare 24-month and 36-month OS rate of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.
Conditions
- Non-Small Cell Lung Cancer
Interventions
Docetaxel + Plinabulin (DP)Drug
Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Docetaxel (D)Drug
Docetaxel 75 mg/m2 IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: The time (Days) from the date of randomization to the date of death, up to 48 months
Locations
57 sites in 3 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers
Chandler, Arizona
Pacific Cancer Medical Center, Inc.
Anaheim, California
Innovative Clinical Research Institute
Whittier, California
Memorial Health Care System
Colorado Springs, Colorado
Cancer Center of Central Connecticut
Plainville, Connecticut
Peachtree Hematoloy-Oncology Consultants, PC
Atlanta, Georgia
Orchard Healthcare Research Inc.
Skokie, Illinois
Carle Cancer Center
Urbana, Illinois
Kansas University Medical Center
Westwood, Kansas
University of Louisville-Brown Cancer Center
Louisville, Kentucky
Henry Ford Hospital
Detroit, Michigan
Michigan Center of Medical Research
Farmington Hills, Michigan
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi
Central Care Cancer Center
Bolivar, Missouri
Wake Forest Baptist Health
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Toledo Cancer Center
Toledo, Ohio
Allegheny Health Network
Pittsburgh, Pennsylvania
Cookeville Regional Medical Center Cancer Center
Cookeville, Tennessee
Blacktown Cancer Centre
Blacktown, New South Wales, Australia
Border Medical Oncology Research Unit
East Albury, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Adult Mater Hospital
South Brisbane, Queensland, Australia
Peninsula and South East Oncology
Melbourne, Victoria, Australia
Epworth Hospital
Richmond, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Perth Oncology/Mount Hospital
Perth, Western Australia, Australia
St John of God Hospital, Subiaco
Subiaco, Western Australia, Australia
Anhui Provincial Hospital
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The PLA General Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Zhongshan Hospital Xiamen University
Xiamen, Fujian, China
Guizhou Provincial Hospital
Guiyang, Guizhou, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Affiliated Cancer Hospital of Harbin Medical Unive
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The Second Xiangya Hospital of Central South Unive
Changsha, Hunan, China
Jiangyin People's Hospital
Jiangyin, Jiangsu, China
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.